DK
Therapeutic Areas
4TEEN4 Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| invobenitug (procizumab) | Cardiogenic Shock (patients with elevated cDPP3) | Phase 1b/2a |
Leadership Team at 4TEEN4 Pharmaceuticals
DA
Dr. Andreas Bergmann
Chief Executive Officer (CEO)
PM
Prof. Mahir Karakas
Chief Medical Officer (CMO)
DJ
Dr. Joachim Struck
Chief Research Officer (CRO)
DK
Dr. Kilian von Seldeneck
Chief Financial Officer (CFO)
DC
Dr. Chris Springer
Chief Operating Officer (COO)